JP2013542191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542191A5 JP2013542191A5 JP2013529669A JP2013529669A JP2013542191A5 JP 2013542191 A5 JP2013542191 A5 JP 2013542191A5 JP 2013529669 A JP2013529669 A JP 2013529669A JP 2013529669 A JP2013529669 A JP 2013529669A JP 2013542191 A5 JP2013542191 A5 JP 2013542191A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- seq
- thalidomide
- combination according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38661910P | 2010-09-27 | 2010-09-27 | |
| US61/386,619 | 2010-09-27 | ||
| EP10180485 | 2010-09-27 | ||
| EP10180485.4 | 2010-09-27 | ||
| US201161437696P | 2011-01-31 | 2011-01-31 | |
| US61/437,696 | 2011-01-31 | ||
| US201161468607P | 2011-03-29 | 2011-03-29 | |
| US61/468,607 | 2011-03-29 | ||
| US201161486814P | 2011-05-17 | 2011-05-17 | |
| US61/486,814 | 2011-05-17 | ||
| PCT/EP2011/066648 WO2012041800A1 (en) | 2010-09-27 | 2011-09-26 | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016206756A Division JP6231642B2 (ja) | 2010-09-27 | 2016-10-21 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542191A JP2013542191A (ja) | 2013-11-21 |
| JP2013542191A5 true JP2013542191A5 (enExample) | 2014-11-13 |
| JP6087283B2 JP6087283B2 (ja) | 2017-03-01 |
Family
ID=43640677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529669A Expired - Fee Related JP6087283B2 (ja) | 2010-09-27 | 2011-09-26 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
| JP2016206756A Active JP6231642B2 (ja) | 2010-09-27 | 2016-10-21 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016206756A Active JP6231642B2 (ja) | 2010-09-27 | 2016-10-21 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8877899B2 (enExample) |
| EP (1) | EP2621531B8 (enExample) |
| JP (2) | JP6087283B2 (enExample) |
| KR (1) | KR101912957B1 (enExample) |
| CN (1) | CN103118706B (enExample) |
| AU (1) | AU2011310696B2 (enExample) |
| BR (1) | BR112013006769B1 (enExample) |
| CA (1) | CA2812631C (enExample) |
| DK (1) | DK2621531T3 (enExample) |
| ES (1) | ES2617446T3 (enExample) |
| HU (1) | HUE031956T2 (enExample) |
| IL (1) | IL224915A (enExample) |
| LT (1) | LT2621531T (enExample) |
| MX (1) | MX350540B (enExample) |
| NZ (1) | NZ607473A (enExample) |
| PL (1) | PL2621531T3 (enExample) |
| PT (1) | PT2621531T (enExample) |
| RU (1) | RU2595839C2 (enExample) |
| SG (1) | SG188345A1 (enExample) |
| SI (1) | SI2621531T1 (enExample) |
| WO (1) | WO2012041800A1 (enExample) |
| ZA (1) | ZA201301232B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287764B (zh) * | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US8877899B2 (en) * | 2010-09-27 | 2014-11-04 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| HRP20171964T1 (hr) * | 2012-09-25 | 2018-02-23 | Morphosys Ag | Kombinacije i njihova upotreba |
| US9486547B2 (en) | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US9963515B2 (en) | 2013-04-29 | 2018-05-08 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| JP2017506640A (ja) * | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| EP3154581B1 (en) | 2014-06-16 | 2019-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells |
| WO2016040294A2 (en) * | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| CN113527495A (zh) * | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| US10533057B2 (en) | 2015-05-13 | 2020-01-14 | Morphosys Ag | Treatment for multiple myeloma (MM) |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| JP6807606B2 (ja) | 2015-07-16 | 2021-01-06 | インヒブルクス インコーポレイテッド | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
| CN105079776B (zh) * | 2015-09-17 | 2018-09-21 | 中南大学 | 一种石蒜碱和硼替佐米组合物的药物用途 |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CN108699161B (zh) * | 2016-03-04 | 2022-06-03 | 莫佛塞斯公司 | 多发性骨髓瘤中m-蛋白应答的临床评估 |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| EP3661557B1 (en) | 2017-07-31 | 2025-09-03 | Actinium Pharmaceuticals, Inc. | Treatments for a hematological malignancy |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| MX2020007429A (es) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). |
| JP7541974B2 (ja) * | 2018-08-26 | 2024-08-29 | カーディフ・オンコロジー・インコーポレイテッド | Ｐｌｋ１標的のリン酸化状態及びｐｌｋ１阻害剤を用いた癌の治療 |
| TWI924633B (zh) * | 2019-03-15 | 2026-05-11 | 德商莫菲西斯公司 | 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物 |
| WO2020250033A1 (en) | 2019-06-10 | 2020-12-17 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| EP4251282A1 (en) | 2020-11-27 | 2023-10-04 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosis and monitoring of toxic epidermal necrolysis |
| TW202309075A (zh) * | 2021-04-30 | 2023-03-01 | 美商亞得捷歐治療公司 | 對冠狀病毒s蛋白質具特異性之化合物及其用途 |
| US20240425567A1 (en) * | 2021-10-08 | 2024-12-26 | Invivyd, Inc. | Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof |
| TW202430548A (zh) * | 2022-09-29 | 2024-08-01 | 日商武田藥品工業股份有限公司 | Ｃｄ３８結合融合蛋白組合療法 |
| KR20260057078A (ko) | 2023-08-18 | 2026-04-27 | 브리스톨-마이어스 스큅 컴퍼니 | Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| DE19933130A1 (de) | 1999-07-19 | 2001-01-25 | Giesecke & Devrient Gmbh | Operandenstapelspeicher und Verfahren zum Betreiben eines Operandenstapelspeichers |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| JP4361273B2 (ja) | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| DE602006013140D1 (enExample) | 2006-09-28 | 2010-05-06 | Nokia Siemens Networks Gmbh | |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| KR20110028450A (ko) * | 2008-06-16 | 2011-03-18 | 이뮤노젠 아이엔씨 | 새로운 상승 효과 |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| US8877899B2 (en) | 2010-09-27 | 2014-11-04 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
-
2011
- 2011-09-26 US US13/825,325 patent/US8877899B2/en active Active
- 2011-09-26 ES ES11761360.4T patent/ES2617446T3/es active Active
- 2011-09-26 NZ NZ607473A patent/NZ607473A/en unknown
- 2011-09-26 PL PL11761360T patent/PL2621531T3/pl unknown
- 2011-09-26 SG SG2013015235A patent/SG188345A1/en unknown
- 2011-09-26 CA CA2812631A patent/CA2812631C/en active Active
- 2011-09-26 WO PCT/EP2011/066648 patent/WO2012041800A1/en not_active Ceased
- 2011-09-26 AU AU2011310696A patent/AU2011310696B2/en active Active
- 2011-09-26 CN CN201180043775.1A patent/CN103118706B/zh active Active
- 2011-09-26 PT PT117613604T patent/PT2621531T/pt unknown
- 2011-09-26 SI SI201131109A patent/SI2621531T1/sl unknown
- 2011-09-26 BR BR112013006769-1A patent/BR112013006769B1/pt active IP Right Grant
- 2011-09-26 MX MX2013003304A patent/MX350540B/es active IP Right Grant
- 2011-09-26 RU RU2013113933/15A patent/RU2595839C2/ru active
- 2011-09-26 JP JP2013529669A patent/JP6087283B2/ja not_active Expired - Fee Related
- 2011-09-26 HU HUE11761360A patent/HUE031956T2/en unknown
- 2011-09-26 KR KR1020137010537A patent/KR101912957B1/ko active Active
- 2011-09-26 LT LTEP11761360.4T patent/LT2621531T/lt unknown
- 2011-09-26 DK DK11761360.4T patent/DK2621531T3/en active
- 2011-09-26 EP EP11761360.4A patent/EP2621531B8/en active Active
-
2013
- 2013-02-18 ZA ZA2013/01232A patent/ZA201301232B/en unknown
- 2013-02-26 IL IL224915A patent/IL224915A/en active IP Right Grant
-
2014
- 2014-09-29 US US14/500,366 patent/US9289490B2/en active Active
-
2016
- 2016-02-05 US US15/016,330 patent/US9765152B2/en active Active
- 2016-10-21 JP JP2016206756A patent/JP6231642B2/ja active Active
-
2017
- 2017-08-07 US US15/670,811 patent/US10308722B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
| JP2013542194A5 (enExample) | ||
| JP2017048208A5 (enExample) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| JP2016506388A5 (enExample) | ||
| ME02798B (me) | Protutijela protiv dkk-1" | |
| JP2012523417A5 (enExample) | ||
| IL273678B1 (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor | |
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2015530399A5 (enExample) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| NZ574978A (en) | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| MX348581B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| NZ705848A (en) | Anti-cd38 antibodies | |
| JP2017528462A5 (enExample) | ||
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| SI3042917T1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| JP2017507954A5 (enExample) | ||
| AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения | |
| RU2014103492A (ru) | Комбинированная терапия антителом к cd19 и азотистым ипритом |